Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Bio-Rad Laboratories stock in Canada | $602.37
Own Bio-Rad Laboratories shares in just a few minutes.
Bio-Rad Laboratories is a medical devices business based in the US. Bio-Rad Laboratories stocks (BIO.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $602.37 – an increase of 1.59% over the previous week. Bio-Rad Laboratories employs 7,800 staff and has a trailing 12-month revenue of around $2.7 billion.
How to buy Bio-Rad Laboratories stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: BIO in this case.
- Research Bio-Rad Laboratories stocks. The platform should provide the latest information available.
- Buy your Bio-Rad Laboratories stocks. It's that simple.
What's in this guide?
- Can I buy shares in Bio-Rad Laboratories?
- Has coronavirus impacted Bio-Rad Laboratories shares?
- Bio-Rad Laboratories shares summary
- Compare share dealing platforms
- Is Bio-Rad Laboratories stock a buy or sell?
- Bio-Rad Laboratories performance over time
- Can I short Bio-Rad Laboratories shares?
- Is Bio-Rad Laboratories suitable for ethical investing?
- Are Bio-Rad Laboratories shares over-valued?
- Bio-Rad Laboratories's financials
- How volatile are Bio-Rad Laboratories shares?
- Does Bio-Rad Laboratories pay a dividend?
- Have Bio-Rad Laboratories shares ever split?
- Other common questions
How has Coronavirus impacted Bio-Rad Laboratories's stock price?
Since the stock market crash in March caused by coronavirus, Bio-Rad Laboratories's stock price has had significant positive movement.
Its last market close was $602.37, which is 33.51% up on its pre-crash value of $400.5 and 94.70% up on the lowest point reached during the March crash when the stocks fell as low as $309.3801.
If you had bought $1,000 worth of Bio-Rad Laboratories stocks at the start of February 2020, those stocks would have been worth $897.44 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,656.52.
Bio-Rad Laboratories stock priceUse our graph to track the performance of BIO stocks over time.
Bio-Rad Laboratories stocks at a glance
|Latest market close||$602.37|
|52-week range||$425.43 - $689|
|50-day moving average||$603.7954|
|200-day moving average||$590.824|
|Wall St. target price||$755|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$135.872|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Bio-Rad Laboratories stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Bio-Rad Laboratories price performance over time
|1 month (2021-05-13)||1.93%|
|3 months (2021-03-12)||7.57%|
|6 months (2020-12-11)||6.19%|
|1 year (2020-06-12)||34.20%|
|2 years (2019-06-13)||101.64%|
|3 years (2018-06-13)||100.08%|
|5 years (2016-06-13)||315.89%|
Is Bio-Rad Laboratories under- or over-valued?
Valuing Bio-Rad Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bio-Rad Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bio-Rad Laboratories's P/E ratio
Bio-Rad Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Bio-Rad Laboratories stocks trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stocks or simply that they're under-valued.
Bio-Rad Laboratories's PEG ratio
Bio-Rad Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.7501. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bio-Rad Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Bio-Rad Laboratories's EBITDA
Bio-Rad Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$647.8 million.
The EBITDA is a measure of a Bio-Rad Laboratories's overall financial performance and is widely used to measure a its profitability.
Bio-Rad Laboratories financials
|Revenue TTM||USD$2.7 billion|
|Operating margin TTM||18.91%|
|Gross profit TTM||USD$1.4 billion|
|Return on assets TTM||2.82%|
|Return on equity TTM||48.49%|
|Market capitalisation||USD$17.7 billion|
TTM: trailing 12 months
How to short and sell Bio-Rad Laboratories stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "BIO.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 521,426 Bio-Rad Laboratories stocks held short by investors – that's known as Bio-Rad Laboratories's "short interest". This figure is 12.1% down from 592,970 last month.
There are a few different ways that this level of interest in shorting Bio-Rad Laboratories stocks can be evaluated.
Bio-Rad Laboratories's "short interest ratio" (SIR)
Bio-Rad Laboratories's "short interest ratio" (SIR) is the quantity of Bio-Rad Laboratories stocks currently shorted divided by the average quantity of Bio-Rad Laboratories stocks traded daily (recently around 136498.95287958). Bio-Rad Laboratories's SIR currently stands at 3.82. In other words for every 100,000 Bio-Rad Laboratories stocks traded daily on the market, roughly 3820 stocks are currently held short.
However Bio-Rad Laboratories's short interest can also be evaluated against the total number of Bio-Rad Laboratories stocks, or, against the total number of tradable Bio-Rad Laboratories stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bio-Rad Laboratories's short interest could be expressed as 0.02% of the outstanding stocks (for every 100,000 Bio-Rad Laboratories stocks in existence, roughly 20 stocks are currently held short) or 0.0247% of the tradable stocks (for every 100,000 tradable Bio-Rad Laboratories stocks, roughly 25 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Bio-Rad Laboratories.
Find out more about how you can short Bio-Rad Laboratories stock.
Bio-Rad Laboratories's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bio-Rad Laboratories.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Bio-Rad Laboratories's total ESG risk score
Total ESG risk: 23.57
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bio-Rad Laboratories's overall score of 23.57 (as at 01/01/2019) is pretty good – landing it in it in the 28th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Bio-Rad Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Bio-Rad Laboratories's environmental score
Environmental score: 6.03/100
Bio-Rad Laboratories's environmental score of 6.03 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Bio-Rad Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Bio-Rad Laboratories's social score
Social score: 16.8/100
Bio-Rad Laboratories's social score of 16.8 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Bio-Rad Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Bio-Rad Laboratories's governance score
Governance score: 10.75/100
Bio-Rad Laboratories's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Bio-Rad Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Bio-Rad Laboratories's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Bio-Rad Laboratories scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bio-Rad Laboratories has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||23.57|
|Total ESG percentile||27.74|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
|Level of controversy||2|
Bio-Rad Laboratories stock dividends
We're not expecting Bio-Rad Laboratories to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Have Bio-Rad Laboratories stocks ever split?
Bio-Rad Laboratories stocks were split on a 2:1 basis on 8 March 2002. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Bio-Rad Laboratories stocks – just the quantity. However, indirectly, the new 50% lower stock price could have impacted the market appetite for Bio-Rad Laboratories stocks which in turn could have impacted Bio-Rad Laboratories's stock price.
Bio-Rad Laboratories stock price volatility
Over the last 12 months, Bio-Rad Laboratories's stocks have ranged in value from as little as $425.43 up to $689. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Bio-Rad Laboratories's is 0.8283. This would suggest that Bio-Rad Laboratories's stocks are less volatile than average (for this exchange).
Bio-Rad Laboratories overview
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Frequently asked questions
More on investing
Find out about gold ETFs, what influences their prices, how you can trade them and whether they could be worth your weight in gold.Read more…
Impact investing is perhaps the purest form of responsible investing. Want to know why? Read our guide to find out.Read more…
Find out what a short squeeze is and how to trade a short squeeze. We’ve detailed how they work, some examples and the high risks involved.Read more…
More guides on Finder
How to buy Atara Biotherapeutics (ATRA) stock in Canada | $14.40
Steps to owning and managing ATRA, with 24-hour and historical pricing before you buy.
How to buy Alnylam Pharmaceuticals (ALNY) stock in Canada | $165.02
Steps to owning and managing ALNY, with 24-hour and historical pricing before you buy.
How to buy Zogenix (ZGNX) stock in Canada | $18.20
Steps to owning and managing ZGNX, with 24-hour and historical pricing before you buy.
How to buy Voyager Therapeutics (VYGR) stock in Canada | $4.73
Steps to owning and managing VYGR, with 24-hour and historical pricing before you buy.
How to buy Vornado Realty Trust (VNO) stock in Canada | $50.01
Steps to owning and managing VNO, with 24-hour and historical pricing before you buy.
How to buy Salem Media Group (SALM) stock in Canada | $2.60
Steps to owning and managing SALM, with 24-hour and historical pricing before you buy.
How to buy HireQuest (HQI) stock in Canada | $20.46
Steps to owning and managing HQI, with 24-hour and historical pricing before you buy.
How to buy Brady (BRC) stock in Canada | $59.52
Steps to owning and managing BRC, with 24-hour and historical pricing before you buy.
How to buy Accelerate Diagnostics (AXDX) stock in Canada | $8.75
Steps to owning and managing AXDX, with 24-hour and historical pricing before you buy.
How to buy Univar Solutions (UNVR) stock in Canada | $27.56
Steps to owning and managing UNVR, with 24-hour and historical pricing before you buy.
Ask an Expert
You must be logged in to post a comment.